Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Archives of Dermatology

• Publication date

  2001-05-01

• Fields of study

  Medicine

• Identifiers
  PMID 11346336
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interferon in the treatment of cutaneous T‐cell lymphoma

  2003cited by this paper
• Treatment of Cutaneous T Cell Lymphoma

  2002cited by this paper
• Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.

  2001cited by this paper
• Association between Sézary T Cell‐activating Factor, Chlamydia pneumoniae, and Cutaneous T Cell Lymphoma

  2001cited by this paper
• Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

  2001cited by this paper
• Emerging new therapies for cutaneous T-cell lymphoma.

  2000cited by this paper
• Can dermatopathologists reliably make the diagnosis of mycosis fungoides? If not, who can?

  2000cited by this paper
• Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients.

  2000cited by this paper
• The changing survival of patients with mycosis fungoides

  1999cited by this paper
• Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses.

  1999cited by this paper
• Central hypothyroidism associated with retinoid X receptor-selective ligands.

  1999cited by this paper
• A Phase I study of LGD1069 in adults with advanced cancer.

  1999cited by this paper
• Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients.

  1999cited by this paper
• Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides.

  1999cited by this paper
• The changing survival of patients with mycosis fungoides

  1999cited by this paper
• Sézary T-Cell Activating Factor Is aChlamydia pneumoniae-Associated Protein

  1999cited by this paper
• Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality.

  1999cited by this paper
• Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides.

  1999cited by this paper
• Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells.

  1999cited by this paper
• Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids.

  1998cited by this paper
• Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II.

  1998cited by this paper
• Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.

  1998cited by this paper
• Topical corticosteroids for mycosis fungoides. Experience in 79 patients.

  1998cited by this paper
• Advances in the management of cutaneous T-cell lymphoma.

  1998cited by this paper
• Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.

  1998cited by this paper
• Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-tumor response in early primary cutaneous T-cell lymphoma.

  1997cited by this paper
• Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion.

  1997cited by this paper
• Initial clinical trial of a selective retinoid X receptor ligand, LGD1069.

  1997cited by this paper
• Association of Erythrodermic Cutaneous T-Cell Lymphoma, Superantigen-Positive Staphylococcus aureus, and Oligoclonal T-Cell Receptor Vβ Gene Expansion

  1997cited by this paper
• HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma.

  1996cited by this paper
• Retinoids increase human apolipoprotein A-11 expression through activation of the retinoid X receptor but not the retinoic acid receptor

  1996cited by this paper
• Mycosis fungoides and Sezary syndrome.

  1996cited by this paper
• Combined modality therapy for cutaneous T-cell lymphoma.

  1996cited by this paper
• Treatment of cutaneous T‐cell lymphoma with extracorporeal photochemotherapy

  1996cited by this paper
• The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens.

  1996cited by this paper
• Cutaneous T-cell lymphoma in association with silicone breast implants.

  1995cited by this paper
• Activation of retinoid X receptors induces apoptosis in HL-60 cell lines

  1995cited by this paper
• Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.

  1995cited by this paper
• The molecular and genetic dissection of the retinoid signaling pathway.

  1995cited by this paper
• The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease. A study of 50 patients.

  1995cited by this paper
• Prognosis and staging of cutaneous T-cell lymphoma.

  1995cited by this paper
• Separation of Transactivation and AP1 Antagonism Functions of Retinoic Acid Receptor (*)

  1995cited by this paper
• Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma?

  1995cited by this paper
• Profound deficiency in normal circulating T cells in erythrodermic cutaneous T-cell lymphoma.

  1994cited by this paper
• The Histologic Spectrum of Mycosis Fungoides/Sézary Syndrome (Cutaneous T‐Cell Lymphoma): A Review of 222 Biopsies, Including Newly Described Patterns and the Earliest Pathologic Changes

  1994influential reference
• Systemic Therapy of Cutaneous T-Cell Lymphomas (Mycosis Fungoides and the Sezary Syndrome)

  1994cited by this paper
• Emergence of leprosy in a patient with mycosis fungoides.

  1994cited by this paper
• Mycosis fungoides skin lesions contain CD8+ tumor‐infiltrating lymphocytes expressing an activated, MHC‐restricted cytotoxic T‐lymphocyte phenotype

  1994cited by this paper
• Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids.

  1994cited by this paper
• Treatment of cutaneous T-cell lymphoma.

  1994cited by this paper
• Presence of Epstein-Barr virus in cutaneous lesions of mycosis fungoides and Sézary syndrome.

  1994cited by this paper
• Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome).

  1994cited by this paper
• Interferon treatment of cutaneous T‐cell lymphoma

  1993cited by this paper
• Characterization of three RXR genes that mediate the action of 9-cis retinoic acid.

  1992cited by this paper
• Infections complicating mycosis fungoides and Sézary syndrome.

  1992cited by this paper
• Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells.

  1992cited by this paper
• Stimulation of cutaneous T-cell lymphoma cells with superantigenic staphylococcal toxins.

  1992cited by this paper
• Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors

  1992cited by this paper
• Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling

  1992cited by this paper
• The treatment of 45 patients with cutaneous T‐cell lymphoma with low doses of interferon‐α2a and etretinate

  1991cited by this paper
• Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid).

  1991cited by this paper
• Retinoic acid receptor gene expression in human skin.

  1991cited by this paper
• Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids.

  1991cited by this paper
• A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides.

  1989cited by this paper
• Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group.

  1989cited by this paper
• The effect of isotretinoin in six patients with cutaneous T-cell lymphoma.

  1987cited by this paper
• Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results.

  1987cited by this paper
• Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides).

  1987cited by this paper
• Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group.

  1987cited by this paper
• Treatment of mycosis fungoides with isotretinoin.

  1986cited by this paper
• 13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group.

  1984cited by this paper
• Association of HLA-DR5 with mycosis fungoides.

  1983cited by this paper
• Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid.

  1983cited by this paper
• Analysis of non‐Hodgkin's lymphomas with nodular and favorable histologies, stages I and II

  1983cited by this paper
• Isotretinoin in cutaneous T-cell lymphoma.

  1983cited by this paper
• Treatment of mycosis fungoides with isotretinoin.

  1983cited by this paper
• Oral retinoid in combination with bleomycin, cyclophosphamide, prednisone and transfer factor in mycosis fungoides.

  1982cited by this paper
• Measuring the quality of life of cancer patients: a concise QL-index for use by physicians.

  1981cited by this paper
• Phenotypic characterization of cutaneous T-cell lymphoma. Use of monoclonal antibodies to compare with other malignant T cells.

  1981cited by this paper
• Septicemic complications of the cutaneous T-cell lymphomas.

  1981cited by this paper
• Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma

  1980cited by this paper
• Prospective staging evaluation of patients with cutaneous T-cell lymphomas. Demonstration of a high frequency of extracutaneous dissemination.

  1980cited by this paper
• Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders.

  1975cited by this paper
• Mycosis fungoides—a disease of antigen persistence

  1974cited by this paper

• Vitamins and the Skin: Vitamin A and Retinoids in Dermatology.

  2026cites this paper
• Comparative evaluation of the biological characteristics of a novel retinoid X receptor agonist and bexarotene.

  2025cites this paper
• Relapsed/refractory mycosis fungoides and Sezary syndrome: biology, clinical manifestations and therapeutic options.

  2025cites this paper
• Repurposing the composite assessment of index lesion severity scoring system in cutaneous lichen planus

  2025cites this paper
• New nonchemotherapy treatment options for cutaneous T-cell lymphomas an update

  2025cites this paper
• Janus kinase inhibitors – a role for the treatment of cutaneous T-cell lymphomas?

  2025cites this paper
• Japanese Dermatological Association Guidelines: Outlines of Japanese Guidelines for the Management of Primary Cutaneous Lymphomas 2025

  2025cites this paper
• Dual Anti-inflammatory Actions of a Novel Retinoid X Receptor Agonist Derived from a Natural Compound in Microglial Cells.

  2025cites this paper
• Enhancer Profiling Reveals a Protective Role of RXRα Against Calcium Oxalate‐Induced Crystal Deposition and Kidney Injury

  2025cites this paper
• Defining Core Concepts for Health‐Related Quality of Life for Patients With Mycosis Fungoides and Sézary Syndrome: A Systematic Literature Review

  2025cites this paper
• Targeting macrophage polarization by inhibiting Pim2 alleviates inflammatory arthritis via metabolic reprogramming

  2025cites this paper
• Thyroid hormones contribute to JAK/STAT pathway abnormal activation, promoting T-cell lymphoma dissemination

  2025cites this paper
• Management of Mycosis Fungoides and Sézary Syndrome With Oral Systemic Therapies

  2025cites this paper
• Cardiodermatology: the heart of the connection between the skin and cardiovascular disease.

  2024influential citation
• Effects of Body Mass Index on Hypertriglyceridemia Associated with Oral Bexarotene Therapy: A Post Hoc Analysis of an Open-Label Comparative Clinical Study of Combined Bexarotene and Phototherapy Versus Bexarotene Monotherapy for Japanese Patients with Cutaneous T-Cell Lymphoma

  2024cites this paper
• Experience with bexarotene to treat cutaneous T-cell lymphomas: a study of the Spanish Working Group of Cutaneous Lymphomas.

  2024cites this paper
• Retinoid Therapy for Neuroblastoma: Historical Overview, Regulatory Challenges, and Prospects

  2024cites this paper
• Rapid response of lichen planus to baricitinib associated with suppression of cytotoxic CXCL13+CD8+ T cells

  2024cites this paper
• Bexarotene-induced hypothyroidism and dyslipidemia; a nation-wide study.

  2024cites this paper
• Compatibility study of topical 0.25% hypericin (HyBryteTM) application in subjects with mycosis fungoides: Results of the HPN‐CTCL‐02 study

  2024cites this paper
• What’s New in Cutaneous T-Cell Lymphoma-Associated Pruritus

  2023cites this paper
• Regulation of adipogenesis through retinoid X receptor and/or peroxisome proliferator-activated receptor by designed lignans based on natural products in 3T3–L1 cells

  2023cites this paper
• Mycosis fungoides: Review and updates

  2023cites this paper
• Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo

  2023cites this paper
• EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2023.

  2023cites this paper
• Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas

  2023cites this paper
• Impact of body mass index on the severity of bexarotene‐associated hypertriglyceridemia: A post hoc analysis of an open‐labeled clinical study of combined bexarotene and phototherapy in Japanese patients with cutaneous T‐cell lymphoma

  2023cites this paper
• Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments

  2023cites this paper
• What Is New in Cutaneous T Cell Lymphoma?

  2023cites this paper
• Retinoid X receptor agonists as selective modulators of the immune system for the treatment of cancer.

  2023cites this paper
• Drug screening identifies tazarotene and bexarotene as therapeutic agents in multiple sulfatase deficiency

  2023cites this paper
• Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study

  2023cites this paper
• SOHO State-of-the-Art Updates and Next Questions: A Modern Approach to the Systemic Treatment of Advanced CTCL.

  2023cites this paper
• Chromatin accessibility dynamics dictate renal tubular epithelial cell response to injury

  2022cites this paper
• Traitements immunomodulateurs du mycosis fongoïde aux stades précoces

  2022cites this paper
• The Use of Retinoids for the Prevention and Treatment of Skin Cancers: An Updated Review

  2022cites this paper
• Conformationally Defined Rexinoids for the Prevention of Inflammation and Nonmelanoma Skin Cancers.

  2022cites this paper
• Mogamulizumab and bexarotene are a promising association for the treatment of advanced cutaneous T-cell lymphomas: a case series.

  2022cites this paper
• Next-generation retinoid X receptor agonists increase ATRA signaling in organotypic epithelium cultures and have distinct effects on receptor dynamics

  2022cites this paper
• Remembering your A, B, C's: Alzheimer's disease and ABCA1

  2022cites this paper
• Comparison of the Efficacy and Safety of Bexarotene and Photo(Chemo)Therapy Combination Therapy and Bexarotene Monotherapy for Cutaneous T-Cell Lymphoma

  2022cites this paper
• Rexinoids Modulate Effector T Cell Expression of Mucosal Homing Markers CCR9 and α4β7 Integrin and Direct Their Migration In Vitro

  2022cites this paper
• Analyses of Ocular Adverse Reactions Associated With Anticancer Drugs Based on the Japanese Pharmacovigilance Database

  2022cites this paper
• The Treatment of Advanced-Stage Mycosis Fungoides and Sezary Syndrome: a Hematologist’s Point of View

  2022cites this paper
• S2k‐Guidelines – Cutaneous lymphomas (ICD10 C82 ‐ C86): Update 2021

  2022cites this paper
• Quantitative Analysis of Immune-Reactive Cells among Leukocytes Is Useful for the Diagnosis of Drug Eruptions Caused by Bexarotene

  2022cites this paper
• Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer.

  2022cites this paper
• S2k‐Leitlinie – Kutane Lymphome (ICD10 C82–C86): Update 2021

  2022cites this paper
• Mycosis fungoides und Sézary‐Syndrom

  2021cites this paper
• How we treat mycosis fungoides and Sézary syndrome.

  2021cites this paper
• How to Sequence Therapies in Mycosis Fungoides

  2021cites this paper
• Alitretinoin in the treatment of cutaneous T‐cell lymphoma

  2021cites this paper
• Safety and efficacy of bexarotene for Japanese patients with cutaneous T‐cell lymphoma: Real‐world experience from post‐marketing surveillance

  2021cites this paper
• Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study.

  2021cites this paper
• Mycosis fungoides and Sézary syndrome

  2021cites this paper
• Cutaneous T cell lymphoma

  2021cites this paper
• Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy

  2021cites this paper
• Mycosis Fungoides in Children and Adolescents: A Systematic Review.

  2021cites this paper
• Clinical characteristics and outcomes of black patients with mycosis fungoides and Sézary syndrome: a subgroup analysis of the phase III MAVORIC trial

  2021cites this paper
• Potential therapeutic uses of rexinoids.

  2021cites this paper
• Targeting the TR4 nuclear receptor with antagonist bexarotene can suppress the proopiomelanocortin signalling in AtT‐20 cells

  2021cites this paper
• Cost-effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma.

  2021cites this paper
• New nonchemotherapy treatment options for cutaneous T-cell lymphomas

  2021cites this paper
• Malignancy Risks of Dermatologic Therapies

  2021cites this paper
• Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC.

  2021cites this paper
• How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome

  2021cites this paper
• Promoting and measuring remyelination and neuroprotection in clinical trials of people with multiple sclerosis

  2021cites this paper
• Systemic Retinoids

  2021cites this paper
• Evaluation of Alitretinoin for the Treatment of Mycosis Fungoides and Sézary Syndrome

  2021cites this paper
• Response to Topical Corticosteroid Monotherapy in Mycosis Fungoides.

  2020cites this paper
• Anticancer Drug-induced Thyroid Dysfunction.

  2020cites this paper
• Interventions for mycosis fungoides.

  2020cites this paper
• [Acute pancreatitis under acitretin].

  2020cites this paper
• Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T‐cell lymphoma

  2020cites this paper
• NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.

  2020cites this paper
• Bexarotene: A Rare Cause of Misleading Thyroid Function Tests

  2020cites this paper
• Non-Melanoma Skin Cancer

  2020cites this paper
• Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020

  2020cites this paper
• Novel Therapeutics for Rare Lymphomas

  2020cites this paper
• Hyaluronic Acid Conjugates of Vorinostat and Bexarotene for Treatment of Cutaneous Malignancies

  2020cites this paper
• QSAR MODELING OF DERMAL METABOLITES OF BEXAROTENE ANALOGS

  2020cites this paper
• How do we treat cutaneous T-cell lymphoma?

  2020cites this paper
• Combinations of LXR and RXR agonists induce triglyceride accumulation in human HepaRG cells in a synergistic manner

  2020cites this paper
• Quality of Life, Anxiety, and Depression in Patients With Early-Stage Mycosis Fungoides and the Effect of Oral Psoralen Plus UV-A (PUVA) Photochemotherapy on it

  2020cites this paper
• QSAR modeling for prediction of binding to DNA or proteins of dermal metabolites of newly synthesized hydrazones

  2020cites this paper
• Long‐term efficacy and safety of bexarotene for Japanese patients with cutaneous T‐cell lymphoma: The results of a phase 2 study (B‐1201)

  2019cites this paper
• Ingenol mebutate for mycosis fungoides

  2019cites this paper
• Antiproliferative activity of Pt(IV) complexes with lonidamine and bexarotene ligands attached via succinate-ethylenediamine linker

  2019cites this paper
• Bexarotene‐induced hypothyroidism: Characteristics and therapeutic strategies

  2019cites this paper
• Cutaneous T-Cell Lymphoma: Mycosis Fungoides and Sézary Syndrome

  2019cites this paper
• Cutaneous Lymphomas.

  2019cites this paper
• Drug Effects on the Thyroid.

  2019cites this paper
• A retinoid X receptor partial agonist attenuates pulmonary emphysema and airway inflammation

  2019cites this paper
• Management of cutaneous T‐cell lymphomas: Established and emergent therapies

  2019cites this paper
• An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma

  2018influential citation
• Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome.

  2018cites this paper
• Cutaneous T-Cell Lymphoma: Trends in Radiation Doses and Patterns of Care 2004-2015

  2018cites this paper
• Cutaneous T-Cell Lymphoma

  2018cites this paper
• British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018

  2018cites this paper
• Oral Retinoids in Dermatology

  2018cites this paper